Education
About Us
Working with TipRanks
Follow Us
Oncolytics Biotech (TSE:ONC)
TSX:ONC
Total Valuation
Oncolytics Biotech has a market cap or net worth of $70.00M. The enterprise value is C$88.49M.
Market Cap$70.00M
Enterprise ValueC$88.49M
Share Statistics
Oncolytics Biotech has 86,421,590 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding86,421,590
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Oncolytics Biotech’s return on equity (ROE) is -1.01 and return on invested capital (ROIC) is -97.68%.
Return on Equity (ROE)-1.01
Return on Assets (ROA)-0.71
Return on Invested Capital (ROIC)-97.68%
Return on Capital Employed (ROCE)-0.98
Revenue Per Employee0.00
Profits Per Employee-991.14K
Employee Count28
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Oncolytics Biotech is -4.36. Oncolytics Biotech’s PEG ratio is 0.94.
PE Ratio-4.36
PS Ratio―
PB Ratio4.39
Price to Fair Value4.39
Price to FCF-4.25
Price to Operating Cash Flow-4.26
PEG Ratio0.94
Income Statement
In the last 12 months, Oncolytics Biotech had revenue of 0.00 and earned -27.75M in profits. Earnings per share was -0.41.
Revenue0.00
Gross Profit-403.00K
Operating Income-33.79M
Pretax Income-27.66M
Net Income-27.75M
EBITDA-33.71M
Earnings Per Share (EPS)-0.41
Cash Flow
In the last 12 months, operating cash flow was -20.15M and capital expenditures -84.16K, giving a free cash flow of -20.24M billion.
Operating Cash Flow-20.15M
Free Cash Flow-20.24M
Free Cash Flow per Share-0.23
Dividends & Yields
Oncolytics Biotech pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.30
52-Week Price Change-44.90%
50-Day Moving Average0.90
200-Day Moving Average1.24
Relative Strength Index (RSI)48.35
Average Volume (3m)52.36K
Important Dates
Oncolytics Biotech upcoming earnings date is May 2, 2025, TBA Not Confirmed.
Last Earnings DateMar 7, 2025
Next Earnings DateMay 2, 2025
Ex-Dividend Date―
Financial Position
Oncolytics Biotech as a current ratio of 9.01, with Debt / Equity ratio of 17.78%
Current Ratio9.01
Quick Ratio9.01
Debt to Market Cap0.00
Net Debt to EBITDA1.02
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Oncolytics Biotech has paid 97.00K in taxes.
Income Tax97.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Oncolytics Biotech EV to EBITDA ratio is -2.57, with an EV/FCF ratio of -3.04.
EV to Sales0.00
EV to EBITDA-2.57
EV to Free Cash Flow-3.04
EV to Operating Cash Flow-3.04
Balance Sheet
Oncolytics Biotech has $15.94M in cash and marketable securities with C$0.00 in debt, giving a net cash position of -$14.88M billion.
Cash & Marketable Securities$15.94M
Total DebtC$0.00
Net Cash-$14.88M
Net Cash Per Share-$0.17
Tangible Book Value Per Share$0.41
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Oncolytics Biotech is $5.27, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$5.27
Price Target Upside550.65% Upside
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast―
EPS Growth Forecast0.10%